Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix: The Future of Drug Development, CEO Clip Video

T.RVX

Vancouver, British Columbia--(Newsfile Corp. - December 16, 2021) - Resverlogix Corp. (TSX: RVX) - Donald McCaffrey, President & CEO speaks about the late-stage biotechnology company and their flagship drug - Apabetalone.



Cannot view this video? Visit:
https://b-tv.com/resverlogix-the-future-of-drug-development-btv-investing-news/

Resverlogix Corp. (TSX: RVX)

https://www.resverlogix.com/

About Resverlogix Corp.:

Resverlogix is developing Apabetalone, a first-in-class, epigenetic therapeutic candidate for the potential treatment of COVID-19 and vascular diseases. It is a selective BET (bromodomain and extra-terminal) inhibitor targeting one specific domain in contrast to other experimental multi-domain BET inhibitors. Apabetalone works in preventing and treating disease progression by regulating the expression of disease-causing genes.

About CEO Clips:

CEO Clips is the largest library of publicly traded company CEO videos in Canada and the US. These 90 second video profiles broadcast on national TV and online via 12 financial sites including: Thomson Reuters, Bloomberg, Yahoo! Finance and Stockhouse.com.

BTV - Business Television/CEO Clips

Discover Companies to Invest in

www.b-tv.com

Contact: Trina Schlingmann (604) 664-7401 x 5 trina@b-tv.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/107856